AstraZeneca PLC AZN
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.32% | 8.61% | 9.93% | 8.63% | 13.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.32% | 8.61% | 9.93% | 8.63% | 13.52% |
| Cost of Revenue | 16.89% | 12.30% | 15.07% | 10.86% | 1.14% |
| Gross Profit | 5.42% | 7.82% | 8.83% | 8.14% | 16.36% |
| SG&A Expenses | 9.48% | 9.83% | 5.84% | 3.76% | 3.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -109.49% | -81.48% | -58.82% | 14.74% | -13.96% |
| Total Operating Expenses | 9.18% | 10.01% | 10.03% | 8.63% | 6.44% |
| Operating Income | 2.30% | 4.42% | 9.60% | 8.64% | 38.49% |
| Income Before Tax | 16.27% | 25.57% | 38.96% | 42.70% | 44.40% |
| Income Tax Expenses | 11.35% | 23.94% | 66.84% | 31.45% | 43.11% |
| Earnings from Continuing Operations | 17.33% | 25.91% | 33.55% | 45.33% | 44.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 20.00% | 0.00% | 60.00% | -33.33% | 0.00% |
| Net Income | 17.35% | 25.93% | 33.67% | 45.34% | 44.71% |
| EBIT | 2.30% | 4.42% | 9.60% | 8.64% | 38.49% |
| EBITDA | 5.13% | 5.88% | 9.35% | 8.35% | 21.87% |
| EPS Basic | 17.34% | 25.90% | 33.64% | 45.25% | 44.61% |
| Normalized Basic EPS | 1.73% | 4.18% | 9.55% | 9.25% | 42.47% |
| EPS Diluted | 17.26% | 25.78% | 33.57% | 45.29% | 44.97% |
| Normalized Diluted EPS | 1.74% | 4.20% | 9.60% | 9.32% | 42.55% |
| Average Basic Shares Outstanding | 0.02% | 0.03% | 0.03% | 0.06% | 0.06% |
| Average Diluted Shares Outstanding | 0.02% | 0.02% | -0.02% | 0.00% | 0.00% |
| Dividend Per Share | 3.19% | 3.19% | 3.23% | 3.23% | 5.39% |
| Payout Ratio | -0.15% | -0.21% | -0.26% | -0.26% | -0.26% |